Trial
NCT04155190
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sol-Gel Technologies, Ltd.
Collaborators
—
Condition
Recurrent Basal Cell Carcinoma
Intervention
Patidegib Topical Gel, 2%
Why stopped
Terminated early due to low blinded event rate
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-21